On August 12, Moderna, Inc. rose 5.17% in regular trading, trading at $63.70 per share, with turnover of $142 million. The rally was driven by the dual catalysts of its mRNA flu vaccine approval and better-than-expected second-quarter results.

On the regulatory front, Moderna announced that its seasonal influenza vaccine mFLUSIVA received U.S. FDA approval for use in adults aged 50 and above, marking the company's fourth approved product in the U.S. and the first-ever mRNA vaccine to enter the flu market. The company expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with regulatory reviews ongoing in Australia, Canada, and Europe.

On the earnings front, Moderna reported Q2 EPS of -$1.97, beating the FactSet consensus estimate of -$2.01, while revenue of $145 million significantly exceeded the $102.9 million estimate. The company reiterated its target of 10% year-over-year revenue growth. Multiple investment banks recently raised price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)